Novo Holdings Acquires Stake in Oxford Nanopore Technologies, a UK-Listed Firm
Friday, August 02, 2024
Novo Holdings, a leading global life science investor, has announced a £50 million investment in Oxford Nanopore Technologies. This investment, part of a new equity issue, is expected to be complemented by additional purchases on the secondary market over time, depending on availability and pricing.
Dr. Daniel Mahony, Senior Partner at Novo Holdings, expressed confidence in Oxford Nanopore’s progress and its potential in the biopharmaceutical sector. “Oxford Nanopore has made notable advancements with its technology, which is gaining traction commercially. Our investment highlights our belief in their platform's capabilities, particularly in supporting drug discovery and development with its rapid sequencing and comprehensive data offerings. After thorough evaluation and review of their robust intellectual property, we are excited to support Oxford Nanopore’s future growth.”
Dr. Gordon Sanghera, CEO of Oxford Nanopore, welcomed Novo Holdings as a new investor. “Novo Holdings is a prestigious name in life sciences, and we are pleased to have them on board. Their deep understanding of the biopharmaceutical market, including biomanufacturing—a key area of growth for us—will be instrumental. Our technology provides fast, detailed sequencing which is crucial for advancing biopharmaceuticals. We look forward to leveraging their expertise as we focus on expanding our biopharma sector.”
Oxford Nanopore’s cutting-edge molecular analysis technology is designed for DNA and RNA sequencing. It offers detailed data, including epigenetic insights, with quick, real-time workflows and is both portable and cost-effective. This technology is increasingly applied in life science research and clinical settings, as well as in biopharmaceutical industries.
The company’s innovations have the potential to revolutionize drug discovery and development processes, enhance biological manufacturing, and support large-scale epigenetic studies, with significant implications for healthcare, particularly in understanding and addressing diseases such as cancer.
Source: novoholdings.dk
